Guangzhou Yiyang Biological Technology Co., Ltd.   Report issue

For profit Phase 1
Founded: Guangzhou China (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2017
NCT03330834
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Guangzhou Yiyang Biological Technology Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (1)

pd-l1 car-t cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1